Tehran (IP) – Executive manager of the 'COV-Iran Barkat' vaccine's clinical trial says the COV-Iran Barakat vaccine's efficiency is the same as imported vaccines, and it has no side effects and its immunogenicity is 80 present.

Iran PressIran News: In an interview with Iran Press, Minoo Mohraz stated that 'COV-Iran Barekat' vaccine efficiency was the same as China's Sinopharm, and its immunogenicity was even better.


Read More:

7 countries willing to buy COV-Iran Barakat vaccine: Health official

COV-Iran Barakat efficiency beyond expectations: Executive manager

Iran: COVID-19 claims 198 lives in 24 hrs